To achieve substantial survival benefit in the orthotopic ID8-Vegf-Defb29 ovarian cancer model, we found that chemotherapy had to be complemented by immunomodulators targeting both the innate and adaptive arms of the immune system. This evidence concerns the gene VEGFA and ovarian carcinoma.